BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

Rhea-AI Summary

BioMark Diagnostics (OTCQB: BMKDF) has secured crucial patents in China and Japan for its metabolic liquid biopsy platform designed for early lung cancer detection. The company's technology has demonstrated over 90% sensitivity for early-stage lung cancer detection in a recent study published in the International Journal of Molecular Sciences.

The granted patents (Chinese patent N° ZL 201980092723.X and Japanese patent N° 2023-111262) strengthen BioMark's position in Asia's largest healthcare markets, where the liquid biopsy market is projected to reach US$670 million in China and US$912 million in Japan by 2030.

Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets.

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce the formal grant of patents in both China and Japan. These new patents cover its innovative metabolic liquid biopsy platform for the rapid, non-invasive detection of lung cancer.

The newly granted Chinese patent (N° ZL 201980092723.X) and Japanese patent (N° 2023-111262) cover BioMark's technology for detecting lung cancer by measuring specific metabolite biomarkers. In a recent study published in the International Journal of Molecular Sciences, BioMark's patented platform has shown a market-leading sensitivity of over 90% for early-stage lung cancer. This capability empowers clinicians to deliver fast, actionable results that can significantly improve patient outcomes.

"Securing these patents in two of Asia's largest healthcare markets is a transformational milestone for BioMark," said Rashid Ahmed Bux, President & CEO of BioMark. "Our technology is directly aligned with the next wave of liquid biopsy adoption across the region. These patents not only strengthen our global IP estate but also position us to capture significant commercial and clinical leadership, opening up new opportunities for expansion, technology licensing, and strategic partnerships."

Granting of these strategic intellectual properties comes as Asia's major markets, China and Japan, face high and rising lung cancer rates. The liquid biopsy market in China is forecast to surpass US$670 million by 2030, while Japan is projected to reach over US$912 million by the same year, both with robust double-digit growth. National screening policies and an expanding commitment to advanced diagnostics are driving this rapid adoption.

About BioMark Diagnostics Inc.

BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved of the content of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268168

FAQ

What patents did BioMark (BMKDF) receive in Asia for lung cancer detection?

BioMark received two key patents: Chinese patent N° ZL 201980092723.X and Japanese patent N° 2023-111262 for its metabolic liquid biopsy platform for early lung cancer detection.

What is the accuracy rate of BioMark's lung cancer detection technology?

According to a recent study in the International Journal of Molecular Sciences, BioMark's platform shows over 90% sensitivity for early-stage lung cancer detection.

How large is the liquid biopsy market potential in China and Japan?

The liquid biopsy market is projected to reach US$670 million in China and US$912 million in Japan by 2030.

What type of cancer detection technology does BioMark (BMKDF) use?

BioMark uses a metabolic liquid biopsy platform that measures specific metabolite biomarkers for rapid, non-invasive lung cancer detection.

Why are the Asian patents significant for BioMark Diagnostics?

The patents strengthen BioMark's global IP portfolio and position the company to capture commercial opportunities in two of Asia's largest healthcare markets, enabling expansion, technology licensing, and strategic partnerships.